Navigation Links
Metabolex Announces Election of Kurt von Emster to Board of Directors
Date:4/22/2009

HAYWARD, Calif., April 22 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new therapeutics for the treatment of diabetes and related metabolic disorders, announced that Kurt von Emster has been elected to its Board of Directors.

Mr. von Emster currently serves as a Managing Director of venBio. From November 2000 to March 2009, Mr. von Emster was Managing Director of MPM BioEquities and a Portfolio Manager for the MPM BioEquities Fund. From July 1989 to November 2000, Mr. von Emster was with the Franklin Templeton Group, most recently as a Vice President and Portfolio Manager. Mr. von Emster is currently a member of the board of directors at Somaxon Pharmaceuticals, Inc., and Facet Biotech, both public biotechnology companies. Mr. von Emster is a Chartered Financial Analyst (CFA), a member of the Association for Investment Management and Research and of the Security Analysts of San Francisco. Mr. von Emster received his B.S. degree from the University of California at Santa Barbara.

"Mr. von Emster brings to the Board the perspective of a seasoned private and public company investor," said Harold Van Wart, Ph.D., president and chief executive officer of Metabolex. "We look forward to his input and expertise as the company continues to build upon its recent clinical successes." Mr. von Emster's appointment follows the resignation of Rob Chess from the Board of Directors. Dr. Van Wart added, "I would like to thank Rob for his many valuable contributions to Metabolex during his Board tenure."

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, which has completed a Phase 2 trial in patients with dyslipidemia; and MBX-2982, which has completed a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
2. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
3. Metabolex Names Zhao, Martin to Executive Posts
4. Metabolex Appoints Donald Hill as Chief Financial Officer
5. Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
6. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
7. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
8. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
9. E&K Scientific Announces New Accuflow Product Line
10. Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)
11. International Society for Medical Publication Professionals (ISMPP) Announces First CMPP Exam Window Closes, Next Opportunity in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):